Exin Therapeutics
YC W25 · Active · AI drug discovery platform for neurotherapeutics
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 1910Shared: drug discovery, high throughput, multimodalActiveAI | AI | Active | YCW19 |
 Torpedo TherapeuticsShared: neural activity, neurotechnology, biotechActiveOther | Other | Active | YCW22 |
 Origami Therapeutics, Inc.Shared: drug discovery, therapeutics, biotechActiveOther | Other | Active | YCW22 |
 SynsoryBioShared: therapeutics, biotech, drugActiveOther | Other | Active | YCW24 |
 Gerostate AlphaShared: therapeutics, biotech, diseaseInactiveOther | Other | Inactive | YCS18 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 CircumventShared: neurotechnology, biotech, disorderActiveOther | Other | Active | YCS18 |
 Dorian TherapeuticsShared: therapeutics, biotech, diseaseAcquiredOther | Other | Acquired | YCS18 |
 PiramidalShared: neurotechnology, neural, brainActiveAI | AI | Active | YCW24 |
 Eris BiotechShared: therapeutics, biotech, drugActiveOther | Other | Active | YCW24 |
 WonderTxShared: drug discovery, biotech, diseaseActiveAI | AI | Active | YCS26 |
Also from W25 in AI
All of W25| Company | Category | Status |
|---|---|---|
 DelineateAgents for Accelerated Clinical Trial DesignActiveAI, Devtools | AI, Devtools | Active |
 .WaveContinuous inference for streaming AI modelsActiveAI, Devtools | AI, Devtools | Active |
 10xAI Sales Teams for Dental PracticesActiveAI, Data | AI, Data | Active |
 a0.devWe make mobile apps using AI.ActiveAI, Devtools | AI, Devtools | Active |
 A1Zap by A1BaseThe social network layer for AI appsActiveAI, Devtools | AI, Devtools | Active |
 AdamAI Powered CADActiveAI, Devtools | AI, Devtools | Active |
Founders
- Gabriel Ocana SanteroFounder/CEO
- Marko TvrdicFounder/COO
About Exin Therapeutics
We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.
- YC batch
- W25 · Winter 2025
- Status, per YC
- Active
- Category
- AI
- Team size
- 9
- Location
- San Francisco, CA, USA
- Founded
- 2024
- Checked
- 36m ago
YC tags: Neurotechnology, Biotech, Therapeutics
Exin Therapeutics: questions
Which YC batch was Exin Therapeutics in?
Exin Therapeutics was in Y Combinator's Winter 2025 batch (W25).
Is Exin Therapeutics still active?
Y Combinator lists Exin Therapeutics as active.
Who founded Exin Therapeutics?
Exin Therapeutics's founders, as listed on its YC page: Gabriel Ocana Santero (Founder/CEO), Marko Tvrdic (Founder/COO).
Where is Exin Therapeutics based?
Exin Therapeutics lists San Francisco, CA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.